AU2001253560A1 - Methods of treatment - Google Patents

Methods of treatment

Info

Publication number
AU2001253560A1
AU2001253560A1 AU2001253560A AU5356001A AU2001253560A1 AU 2001253560 A1 AU2001253560 A1 AU 2001253560A1 AU 2001253560 A AU2001253560 A AU 2001253560A AU 5356001 A AU5356001 A AU 5356001A AU 2001253560 A1 AU2001253560 A1 AU 2001253560A1
Authority
AU
Australia
Prior art keywords
treatment
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001253560A
Inventor
Maxwell D. Cummings
Robert W. Marquis Jr.
Yu Ru
Scott K. Thompson
Daniel F. Veber
Dennis S. Yamashita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of AU2001253560A1 publication Critical patent/AU2001253560A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2001253560A 2000-04-18 2001-04-17 Methods of treatment Abandoned AU2001253560A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US19771700P 2000-04-18 2000-04-18
US60197717 2000-04-18
PCT/US2001/012386 WO2001078734A1 (en) 2000-04-18 2001-04-17 Methods of treatment

Publications (1)

Publication Number Publication Date
AU2001253560A1 true AU2001253560A1 (en) 2001-10-30

Family

ID=22730469

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001253560A Abandoned AU2001253560A1 (en) 2000-04-18 2001-04-17 Methods of treatment

Country Status (5)

Country Link
EP (1) EP1303281A4 (en)
JP (1) JP2003531122A (en)
AU (1) AU2001253560A1 (en)
CO (1) CO5280093A1 (en)
WO (1) WO2001078734A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1401453A4 (en) * 2001-05-17 2005-04-06 Smithkline Beecham Corp Protease inhibitors
EP1551823A1 (en) * 2002-10-08 2005-07-13 Merck Frosst Canada Inc. 4-amino-azepan-3-one compounds as cathepsin k inhibitors useful in the treatment of osteoporosis
WO2009087379A2 (en) 2008-01-09 2009-07-16 Amura Therapeutics Limited Tetrahydrofuro (3, 2 -b) pyrrol- 3 -one derivatives as inhibitors of cysteine proteinases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ511710A (en) * 1998-12-23 2003-12-19 Smithkline Beecham Corp 4-Amino-azepan-3-one derivatives useful as protease inhibitors
JP2003513956A (en) * 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション Protease inhibitor
WO2001034160A1 (en) * 1999-11-10 2001-05-17 Smithkline Beecham Corporation Protease inhibitors
AU1474601A (en) * 1999-11-10 2001-06-06 Smithkline Beecham Corporation Protease inhibitors
US6534498B1 (en) * 1999-11-10 2003-03-18 Smithkline Beecham Corporation Protease inhibitors
EP1229912A4 (en) * 1999-11-10 2003-05-07 Smithkline Beecham Corp Protease inhibitors
JP2003513926A (en) * 1999-11-10 2003-04-15 スミスクライン・ビーチャム・コーポレイション Protease inhibitor
JP2003533432A (en) * 1999-11-10 2003-11-11 スミスクライン・ビーチャム・コーポレイション Protease inhibitor
CN1416346A (en) * 2000-03-21 2003-05-07 史密丝克莱恩比彻姆公司 Peotease inhibitors

Also Published As

Publication number Publication date
EP1303281A1 (en) 2003-04-23
EP1303281A4 (en) 2006-02-15
CO5280093A1 (en) 2003-05-30
WO2001078734A1 (en) 2001-10-25
JP2003531122A (en) 2003-10-21

Similar Documents

Publication Publication Date Title
AU2002257936A1 (en) Methods of well treatment
AU2002223827A1 (en) Well treatment
AU2001249881A1 (en) Method of treating the heart
AU2002215125A1 (en) Well treatment method
AU2002332430A1 (en) Methods of treating neuropilin-mediated diseases
GB0014969D0 (en) Novel method of treatment
AU2000260550A1 (en) Treatment of skin damage using polyenylphosphatidylcholine
AU2001286983A1 (en) Method of treatment
AU2002231206A1 (en) Treatment of depression
AU2001245414A1 (en) Treatment of allergies
AU2001262177A1 (en) Method of treatment
AUPR731901A0 (en) Method of treatment
AU2001253560A1 (en) Methods of treatment
AU2001281465A1 (en) Treatment of rosacea
AU4598400A (en) Method of treatment
AU2382601A (en) Novel method of treatment
AUPQ662500A0 (en) Method of treatment
AUPQ949500A0 (en) Method of treatment
AUPR213000A0 (en) Method of treatment
AU2001271537A1 (en) Cough treatment
AUPQ811200A0 (en) Treatment of alopecia
GB0014904D0 (en) Methods of treatment
GB0013928D0 (en) Methods of treatment
AU2001250000A1 (en) Treatment of vitiligo
AUPR579801A0 (en) Method of treatment